Literature DB >> 35350672

Primary Sclerosing Cholangitis Complicated with Aphthoid Colitis Difficult to Diagnose from IgG4-Related Sclerosing Cholangitis.

Jin Imai1,2, Hitoshi Ichikawa2,3, Motoki Kaneko1,2, Hiroyuki Ito2, Shinji Takashimizu2, Takayuki Shirai2, Takuma Tajiri4, Norihito Watanabe2, Hidekazu Suzuki1.   

Abstract

A 19-year-old man visited our hospital because of diarrhea and blood and liver dysfunction. Magnetic and endoscopic retrograde cholangiography revealed diffuse narrowing of the common biliary tract and intrahepatic biliary tract. A biopsy specimen from the narrowed area of the common biliary tract revealed IgG4-related sclerosing cholangitis (IgG4-SC). Colonoscopy showed multiple aphthoid colitis. He was treated with corticosteroids, and the levels of hepatobiliary enzymes, IgG, and IgG4 gradually decreased. This is an extremely rare case of colitis in which the patient had a phenotype of sclerosing cholangitis similar to IgG4-SC, which was finally diagnosed as primary sclerosing cholangitis.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Aphtoid colitis; IgG4-related sclerosing cholangitis; Primary sclerosing cholangitis

Year:  2022        PMID: 35350672      PMCID: PMC8921940          DOI: 10.1159/000521538

Source DB:  PubMed          Journal:  Case Rep Gastroenterol        ISSN: 1662-0631


Introduction

Sclerosing cholangitis (SC) is defined as a condition with progressive stenosis of the bile ducts due to diffuse inflammation and fibrosis. Primary sclerosing cholangitis (PSC) is of unknown etiology, whereas secondary SC is caused by a variety of pathological conditions, including IgG4-related sclerosing cholangitis (IgG4-SC), which has been established as a clinical phenotype of systemic IgG4-related disease (IgG4-RD) found in the biliary tree [1]. Although the presentation of IgG4-SC and PSC are similar, the comorbidities, treatment response, and outcomes differ significantly; therefore, it is strongly advisable to be familiar with these two diseases to make the correct diagnosis [1]. However, diagnosis of these two diseases is sometimes difficult. Herein, we present a unique SC patient with a phenotype similar to that of IgG4-SC, who was finally diagnosed with PSC.

Case Report

A 19-year-old Japanese man with elevated serum levels of hepatobiliary enzymes was admitted to our hospital. Nine months prior, the patient had visited another hospital because of bloody diarrhea and liver dysfunction. Colonoscopy at the previous hospital revealed multiple aphthae in the terminal ileum including the ileocecal valve and the entire colon (Fig. 1a–d). He was suspected of having inflammatory bowel disease (IBD) and started taking mesalazine and ursodeoxycholic acid for liver dysfunction. Although his digestive symptoms resolved, the elevated serum levels of hepatobiliary enzymes still kept gradually increasing. He was then recommended to undergo a detailed examination at our hospital.
Fig. 1

The colonoscopy showed multiple aphthae in the terminal ileum (a) including the ileocecal valve (b) and the whole colon (c–d) at the previous doctor. e The abdominal ultrasound revealed the thickness of the common bile duct. f MRCP showed irregular contours of the intrahepatic duct, like a pruned-tree appearance. g ERCP showed irregular narrowing of the common bile duct and intrahepatic duct, and IDUS showed the wall thickness of the common bile duct.

Physical examination at the time of admission revealed no abdominal findings or jaundice. He had no specific problems of past medical history and family history. Blood tests showed serum white blood cell count, 4,800/μL (eosinophils, 360/μL); hemoglobin levels, 13.7/μL; amylase levels, 65 U/L; total bilirubin level, 2.6 mg/dL; AST, 173 IU/L; ALT, 219 IU/L; ALP; 2556 IU/L; γ-GTP, 567 IU/L; IgG levels, 2,421 mg/dL (normal range, 870–1,700 mg/dL); and IgG4 levels, 248 mg/dL (normal range, 4.8–105 mg/dL). Further tests including antinuclear antibodies, antimitochondrial antibodies, hepatitis B, hepatitis C, and tumor markers were negative. Abdominal ultrasonography revealed the thickness of the common bile duct (Fig. 1e), and magnetic resonance cholangiopancreatography (MRCP) showed irregular contours of the intrahepatic duct (pruned-tree appearance) (Fig. 1f), which raised suspicion of PSC. Endoscopic retrograde pancreatocholangiography (ERCP) showed irregular narrowing of the common bile duct and intrahepatic duct, with no narrowing of the main pancreatic duct, and intraductal ultrasonography (IDUS) revealed wall thickening of the common bile duct (Fig. 1g). Histopathological examination of the common bile duct which was collected the transpapillary biopsy specimens under ERCP revealed moderate to severe lymphoplasmacytic infiltration with fibrosis. Immunostaining showed a large number of IgG4-positive plasma cells (more than 30 cells/high-power field) (Fig. 2), indicating the characteristic findings of IgG4-SC. However, considering his episode of bloody diarrhea, the presence of multiple aphthae in the whole colon, and the bile duct images from MRCP and ERCP, a diagnosis of PSC associated with undetermined colitis was suspected. For the treatment of liver dysfunction, he was started on treatment with 20 mg corticosteroids (0.5 mg/kg/day), and the levels of hepatobiliary enzymes, IgG, and IgG4 gradually decreased (Fig. 3a). MRCP showed that the slightly dilated bile ducts were demonstrated mainly in the left intrahepatic bile duct with some narrowing (Fig. 3b).
Fig. 2

a Histopathological examination of the common bile duct revealed moderate to severe lymphoplasmacytic infiltration with fibrosis (H&E stain. ×400) (b) Immunostaining study showed a large number of IgG4-positive plasma cells (more than 30 cells/high-power field) (IgG4 stain. ×400).

Fig. 3

a He was started on treatment with 20 mg corticosteroids, and the levels of hepatobiliary enzymes, IgG, and IgG4 gradually decreased. b MRCP showed that the slightly dilated bile ducts were demonstrated mainly in the left intrahepatic bile duct with some narrowing.

Discussion

Here, we report a rare case of PSC. We noted three important findings in this case. First, this patient showed high serum IgG4 concentration and infiltration of abundant IgG4-positive plasma cells into the bile duct. Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis characterized by a high serum IgG4 concentration and complications that include various extra-pancreatic manifestations, one of which is sclerosing cholangitis [2]. In this case, the abdominal ultrasound and abdominal CT scan did not show inflammatory swelling of the whole pancreas, and ERCP did not show irregular and narrow strictures of the main pancreatic duct, which is characteristic of type 1 AIP [3]. IgG4-SC is one of the most common extra-pancreatic manifestations of type 1 AIP; therefore, IgG4-SC often increased serum IgG4 levels (74%), and abundant IgG4-positive cells are found in bile duct biopsy specimens (88%) [4]. On the other hand, PSC shows lower serum IgG4 levels (9%) [5] or local infiltration of IgG4-positive cells [6]. These findings may be difficult to distinguish between PSC and IgG4-SC. As the IDUS revealed the wall thickening of the lower common bile duct in this case, so we collected the transpapillary biopsy specimens from these lesions under ERCP. Naitoh et al. [7] reported that both IDUS and transpapillary biopsy after ERCP can provide further information rather than only biopsy in the diagnosis of IgG4-SC. Second, this case showed symptomatic multiple aphthoid colitis that resembled IBD before taking mesalazine. The relationship between IBD and hepatobiliary disease is well recognized, especially in PSC [8]. The prevalence of IBD associated with PSC is as high as 60%–80% in Western countries [9], although in Japan, IBD is found in only 21%–37% of PSC cases [10]. However, no association between IBD and IgG4-SC has been reported [11]. Only one study reported that 6% of IgG4-SC cases were associated with IBD in a Western country [12]. As such, an association with IBD is a very useful finding for the diagnosis of PSC. These findings supported the diagnosis of PSC in the present case. Finally, the differential diagnosis of PSC and IgG4-SC is important because patients with IgG4-SC show a good response to steroid therapy [13]. In a systematic review of pediatric IgG4-related disease, the doses of prednisone were usually between 0.5 and 2 mg/kg/day [14]. The present patient showed effective response to steroid therapy (0.5 mg/kg/day). Therefore, this point is most difficult differentiation between PSC and IgG4-SC. However, Chen et al. [15] reported three PSC cases with IBD with a documented response to steroids. Compare to these 3 patients (Table1), this case is similar in that it is young, has enteritis, and is not associated with pancreatic involvement. These findings suggested that there is sometimes no clear diagnosis between PSC and IgG4-SC; however, we must always consider PSC with poor prognosis in these situations [16]; therefore, we finally diagnosed the patient with PSC in this case. Of course, the possibility of IgG4-SC has not been completely denied, so it is necessary to carefully monitor the progress as long term. Further studies are necessary to elucidate these diseases.
Table 1

Case comparison of PSC that responded to steroids

Age/sexAST/ALT/ALP, IU/LSerum IgG4 (over 135 mg/dL)ColitisPancreatic involvement
This case19/male173/219/2,556+Aphtoid colitis
Case 144/male129/58/1,420+Indeterminate colitis
Case 229/male135/103/911Pan-ulcerative colitis
Case 318/female141/174/569Indeterminate colitis

Statement of Ethics

The following research complies with the guidelines for human studies and was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The patient provided informed written consent to publish their case including the publication of the images. This study protocol was reviewed and the need for approval was waived by the Medical Ethics Committee on Human Research of Tokai University School of Medicine.

Conflict of Interest

The authors of this manuscript do not have any conflict of interest to declare.

Funding Sources

This work was supported by Japan Society for the Promotion of Science (19K17413 to J.I.), Takeda Japan Medical Office Funded Research Grant 2019 (J.I.).

Author Contributions

J. Imai, H. Ichikawa, M. Kaneko, H. Ito, S. Takashimizu, T. Sirai, T. Tajiri, and N. Watanabe were responsible for the study concept and design, data collection, discussion, and drafting of the manuscript. J. Imai and H. Ichikawa reassessed the contents and English grammar of the manuscript. H. Suzuki supervised the whole process of the study. All the authors read and approved the final manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.
  16 in total

Review 1.  Autoimmune pancreatitis and IgG4-associated sclerosing cholangitis.

Authors:  Isao Nishimori; Makoto Otsuki
Journal:  Best Pract Res Clin Gastroenterol       Date:  2009       Impact factor: 3.043

2.  Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma.

Authors:  Abdul M Oseini; Roongruedee Chaiteerakij; Abdirashid M Shire; Amaar Ghazale; Joseph Kaiya; Catherine D Moser; Ileana Aderca; Teresa A Mettler; Terry M Therneau; Lizhi Zhang; Naoki Takahashi; Suresh T Chari; Lewis R Roberts
Journal:  Hepatology       Date:  2011-08-08       Impact factor: 17.425

3.  Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy.

Authors:  Einar Björnsson; Suresh Chari; Marina Silveira; Andrea Gossard; Naoki Takahashi; Thomas Smyrk; Keith Lindor
Journal:  Am J Ther       Date:  2011-05       Impact factor: 2.688

4.  Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis.

Authors:  Takahiro Nakazawa; Hirotaka Ohara; Hitoshi Sano; Tomoaki Ando; Shigeru Aoki; Shinya Kobayashi; Tetsu Okamoto; Tomoyuki Nomura; Takashi Joh; Makoto Itoh
Journal:  Pancreas       Date:  2005-01       Impact factor: 3.327

5.  ERCP features in 27 patients with autoimmune pancreatitis.

Authors:  Akira Horiuchi; Shigeyuki Kawa; Hideaki Hamano; Masayoshi Hayama; Hiroyoshi Ota; Kendo Kiyosawa
Journal:  Gastrointest Endosc       Date:  2002-04       Impact factor: 9.427

6.  IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis?

Authors:  Yoh Zen; Kenichi Harada; Motoko Sasaki; Yasunori Sato; Koichi Tsuneyama; Joji Haratake; Hiroshi Kurumaya; Kazuyoshi Katayanagi; Shinji Masuda; Hideki Niwa; Hideo Morimoto; Atsuo Miwa; Akio Uchiyama; Bernard C Portmann; Yasuni Nakanuma
Journal:  Am J Surg Pathol       Date:  2004-09       Impact factor: 6.394

7.  Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis.

Authors:  Takayoshi Nishino; Hiroyasu Oyama; Etsuko Hashimoto; Fumitake Toki; Itaru Oi; Makio Kobayashi; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

8.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.

Authors:  Amaar Ghazale; Suresh T Chari; Lizhi Zhang; Thomas C Smyrk; Naoki Takahashi; Michael J Levy; Mark D Topazian; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Santhi Swaroop Vege; Keith Lindor; Michael B Farnell
Journal:  Gastroenterology       Date:  2007-12-07       Impact factor: 22.682

Review 9.  Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity?

Authors:  Takahiro Nakazawa; Itaru Naitoh; Kazuki Hayashi; Hitoshi Sano; Katsuyuki Miyabe; Shuya Shimizu; Takashi Joh
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 10.  IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Atsushi Tanaka
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.